Table 3.
Direct treatment cost and QALY loss of HB-related patients under different scenarios
| Direct treatment cost (CNY) |
Loss of QALYs |
|||||
|---|---|---|---|---|---|---|
| HB diseases | Universal vaccination | Nonvaccination | Prevented value | Universal vaccination | No vaccination | Prevented value |
| AHB | 6,417,040.52 | 292,636,257.07 | 286,219,216.55 | 43.82 | 1998.19 | 1954.37 |
| CHB | 47,407,437.29 | 1,213,027,955.08 | 1,165,620,517.79 | 281.70 | 7188.84 | 6907.14 |
| Cirrhosis | 16,124,433.30 | 408,475,499.25 | 392,351,065.95 | 120.81 | 3032.88 | 2912.07 |
| HCC | 11,661,511.70 | 291,868,298.68 | 280,206,786.98 | 29.10 | 708.27 | 679.17 |
| HBV carrier | 5,910,016.05 | 144,381,602.28 | 138,471,586.23 | 249.40 | 6118.90 | 5869.50 |
| total | 87,520,438.86 | 2,350,389,612.36 | 2,262,869,173.50 | 724.83 | 19047.08 | 18322.25 |